According to Fortune Business Insights, the global oral proteins and peptides market was valued at USD 3.36 billion in 2025 and is expected to climb to USD 3.97 billion in 2026, eventually reaching USD 9.17 billion by 2034. This represents a compound annual growth rate (CAGR) of 11.03% across the 2026–2034 forecast window. North America was the standout region in 2025, commanding a market share of 71.72%.
This segment of the pharmaceutical industry centers on protein and peptide-based drugs that are absorbed systemically but delivered through oral tablets or capsules rather than injections. The core value proposition is patient convenience: oral formulations improve treatment adherence, reduce hesitancy tied to needles, and can encourage patients to begin therapy sooner for long-term conditions.
What's Driving Growth
Several forces are pushing this market forward. The commercial rollout of oral semaglutide has demonstrated that injectable biologics can be reformulated for oral use without losing clinical relevance, and this has encouraged wider physician acceptance of oral peptide treatments for diabetes. The approval of oral octreotide for maintaining acromegaly treatment has added further momentum, as has growing investment in delivery technologies capable of converting traditionally injectable biologics into oral versions. Beyond these established products, pipeline activity in oral insulin, oral PTH (parathyroid hormone) analogs, and oral GLP-2 peptides is expanding the market's reach well past its current base of approved therapies.
A broader driver is the rising global burden of chronic disease. Because these therapies primarily target long-term conditions such as type 2 diabetes, obesity, and various endocrine disorders, an expanding patient population translates directly into higher demand for treatments that are easier to initiate and sustain. Global health data reinforces this: the World Health Organization reported in December 2025 that roughly 16% of adults worldwide were living with obesity in 2022, underscoring the scale of the patient pool these therapies serve.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/oral-proteins-and-peptides-market-116018
Challenges and Restraints
Despite strong momentum, the market faces real technical and financial hurdles. Oral proteins are inherently fragile — they tend to break down in the gastrointestinal tract and struggle to cross the intestinal barrier, which limits bioavailability. Overcoming this requires absorption enhancers, protective coatings, or specialized delivery systems, all of which add complexity to dosing and increase variability in clinical results.
This technical difficulty feeds directly into cost. Developing oral peptide products demands significant investment in specialized excipients, delivery platforms, and large-scale clinical trials, along with tighter manufacturing controls. As a result, smaller biotech firms may struggle with funding, while larger companies tend to be more selective about which oral biologic programs they pursue.
Market Segmentation
By drug class, GLP-1 peptides currently hold the largest share, buoyed by their established use in type 2 diabetes and a strong base of approved products — Novo Nordisk's Rybelsus alone generated reported sales of USD 3,407.4 million in 2025. However, PTH analogs are projected to be the fastest-growing category going forward, with a forecast CAGR of 40.24%.
Metabolic disorders represent the leading therapeutic area, reflecting the concentration of approved oral peptide therapies in diabetes care. By age group, adult patients dominate usage, since the chronic conditions these drugs treat are far more prevalent later in life. In terms of formulation, tablets are the clear leader thanks to their convenience and strong physician familiarity, while retail pharmacies and drug stores are the primary distribution channel, supported by their suitability for routine prescription refills.
Regional Landscape
North America remains the largest regional market, valued at roughly USD 2.41 billion in 2025, driven by early product launches, strong prescription infrastructure, and rapid uptake of oral GLP-1 therapies. Europe is expected to grow fastest among major regions, with a projected CAGR of 15.66%, aided by expanding use of oral semaglutide and supportive reimbursement frameworks. Asia Pacific, led by Japan, China, and India, is emerging as the third-largest region, propelled by large diabetic populations and improving access to metabolic treatments.
Competitive Landscape
The market is fairly concentrated, with Novo Nordisk, Chiesi Group, and EnteraBio Ltd. holding prominent positions. Novo Nordisk's leadership stems largely from oral semaglutide, while other players — including Oramed Pharmaceuticals and Rani Therapeutics — are investing in oral insulin, PTH analogs, and other next-generation peptide delivery platforms to build future market share.
Outlook
With regulatory approvals expanding beyond diabetes into areas like weight management and bone health, and delivery technology steadily improving, the oral proteins and peptides market appears positioned for sustained double-digit growth through 2034, provided bioavailability and cost challenges continue to be addressed through innovation.